<DOC>
	<DOCNO>NCT01173497</DOCNO>
	<brief_summary>The purpose study investigate response rate triple negative breast cancer patient brain metastasis INIPARIB use combination irinotecan . Based data generate BiPar/Sanofi , conclude iniparib posse characteristic typical PARP inhibitor class . The exact mechanism yet fully elucidate , however base experiment tumor cell perform laboratory , iniparib novel investigational anti-cancer agent induces gamma-H2AX ( marker DNA damage ) tumor cell line , induces cell cycle arrest G2/M phase tumor cell line , potentiates cell cycle effect DNA damage modality tumor cell line . Investigations potential target iniparib metabolite ongoing .</brief_summary>
	<brief_title>A Study Evaluating INIPARIB Combination With Chemotherapy Treat Triple Negative Breast Cancer Brain Metastasis</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Iniparib</mesh_term>
	<criteria>Inclusion Criteria 1 . Histologicallyconfirmed , ER negative , PR negative Her2 negative adenocarcinoma breast brain lesion radiographic imaging . 2 . ECOG Performance Status 02 . 3 . Life expectancy &gt; 12 week . 4 . No limit prior therapy last anticancer treatment ≥ 2 week initiation protocolbased therapy provide toxicity ( alopecia ) resolve ≤Grade 1 baseline . 5 . No active serious infection comorbid illness would impair ability participate trial . 6 . Stable decrease dose steroid ≥ 7 day . 7 . Interval ≥ 4 week open brain biopsy initiation protocolbased therapy . 8 . Patients must adequate organ function . Exclusion Criteria 1 . Pregnant breastfeed 2 . Prior allergic reaction INIPARIB 3 . Prior allergic reaction irinotecan . 4 . Evidence hemorrhage impend herniation baseline brain image 5 . Evidence diffuse leptomeningeal disease brain MRI previously document CSF cytologyNOTE : discrete dural metastasis permit . 6 . Clinically significant cardiac , renal , hepatic , infectious pulmonary disease might affect trial participation . 7 . Concurrent plan radiation , hormonal , chemotherapeutic , experimental target biologic therapy . 8 . Contraindication gadoliniumenhanced MRI image . 9 . Inability comply study and/or followup procedure .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Triple negative breast cancer</keyword>
	<keyword>Brain metastasis</keyword>
	<keyword>BSI-201</keyword>
	<keyword>iniparib</keyword>
</DOC>